Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Hillevax Inc (HLVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: HLVX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -47.77% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 69.45M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 139901 | Beta 0.75 | 52 Weeks Range 1.37 - 16.30 | Updated Date 04/2/2025 |
52 Weeks Range 1.37 - 16.30 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.89% | Return on Equity (TTM) -70.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -77473627 | Price to Sales(TTM) - |
Enterprise Value -77473627 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.07 | Shares Outstanding 50141100 | Shares Floating 30028884 |
Shares Outstanding 50141100 | Shares Floating 30028884 | ||
Percent Insiders 16.99 | Percent Institutions 72.21 |
Analyst Ratings
Rating 3 | Target Price 3 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Hillevax Inc
Company Overview
History and Background
Hillevax, Inc. is a biopharmaceutical company focused on developing and commercializing novel vaccines. Founded in 2012, it achieved a significant milestone with the development of Vaxelis, a hexavalent combination vaccine. The company continues to innovate in the vaccine space, targeting unmet medical needs.
Core Business Areas
- Vaccine Development: Research, development, and clinical trials for new vaccine candidates.
- Commercialization: Manufacturing, marketing, and distribution of approved vaccines.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical and biotech industries. The organizational structure includes research and development, clinical operations, commercial, and administrative functions.
Top Products and Market Share
Key Offerings
- Vaxelis: A hexavalent combination vaccine protecting against diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B. Competitors include Sanofi's Pentacel and GSK's Infanrix Hexa. It is difficult to obtain precise market share data, but Vaxelis is a significant competitor in the hexavalent vaccine market, estimated at approximately $4 billion globally.
Market Dynamics
Industry Overview
The vaccine industry is characterized by increasing demand due to global health concerns and advancements in vaccine technology. Major players are continuously developing new vaccines and expanding their market presence.
Positioning
Hillevax is positioned as an innovator in the vaccine market, with a focus on combination vaccines. Its competitive advantage lies in its established product, Vaxelis and expertise in vaccine development and potential for expansion.
Total Addressable Market (TAM)
The global vaccine market is expected to reach approximately $100 billion by 2025. Hillevax is positioned to capture a portion of this market through its existing product and pipeline candidates.
Upturn SWOT Analysis
Strengths
- Established product (Vaxelis)
- Expertise in vaccine development
- Strong research and development pipeline
Weaknesses
- Reliance on a single key product
- Competition from larger pharmaceutical companies
- Limited marketing and distribution capabilities compared to larger competitors
Opportunities
- Expansion into new markets
- Development of new vaccine candidates
- Partnerships with other pharmaceutical companies
Threats
- Regulatory hurdles
- Competition from established players
- Patent expirations
Competitors and Market Share
Key Competitors
- SNY
- GSK
- MRK
- PFE
Competitive Landscape
Hillevax faces intense competition from larger, more established pharmaceutical companies. Its success depends on its ability to innovate and effectively commercialize its products.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth driven by the commercialization of Vaxelis.
Future Projections: Future growth dependent on the success of pipeline candidates and market expansion.
Recent Initiatives: Focus on expanding the market reach of Vaxelis and advancing pipeline candidates.
Summary
Hillevax is a growing biopharmaceutical company with a promising vaccine, Vaxelis, that is competing against larger more established players. It is working on new vaccine candidates to expand its portfolio. Hillevax needs to strengthen it's pipeline and expand its commercial reach. It must be cautious and handle the regulatory hurdles as well as the intense competition in the vaccine market.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
GSK
GlaxoSmithKline PLC ADR
GSK
GlaxoSmithKline PLC ADR
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hillevax Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2022-04-29 | Co-Founder, President, CEO & Chairman of the Board Dr. Robert M. Hershberg M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.hillevax.com |
Full time employees 14 | Website https://www.hillevax.com | ||
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.